Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.
 |
Vidyya |
|
Ars Medica Home |
|
Vidyya Archives |
|
Search Vidyya |
|
Ex Libris |
|
Subscriptions |
|
About Vidyya |
|
|
|
In Today's Vidyya |
|
People With Common Masculinizing Disorder Also Lack Adrenaline, NICHD Study Finds People with 21-hydroxylase deficiency — a common yet little known disorder causing early puberty and masculinizing features in both males and females — also lack sufficient quantities of the stress hormone adrenaline, according to a study by researchers at the National Institute of Child Health and Human Development (NICHD). More... |
|
Risk Factors For Brain Tumors In Adults In 1994, the National Cancer Institute (NCI) began a comprehensive study on the causes of brain tumors. The impetus for the study grew out of public concern about cellular telephone use and adult brain tumors which led Congress in 1993 to urge NCI to conduct the study. The study has been updated to include new information as of November, 2000. More... |
|
Abstracts October 2000: Diagnosis, Histopathology And Pathogenesis Of Brain Tumors
The newest information regarding the diagnosis, histopathology and pathogenesis of brain tumors can be found in this set of abstracts. The abstracts are those that have been added to the CANCERLIT database for October, 2000. Every effort has been made to ensure the search strategy used produces the most accurate results, so that you can read the information you need quickly and get on with your day. More... |
|
Information For Patients - Brain Tumors Each year more than 17,000 people in the United States find out they have a brain tumor. The National Cancer Institute (NCI) has written this booklet to help patients and their families and friends better understand brain tumors. We also hope others will read it to learn more about these tumors. This booklet describes the symptoms, diagnosis, and treatment of brain tumors. More... |
|
Additional Drug For Erectile Dysfunction Under Investigation TAP Pharmaceutical Products Inc. today announced that it has in-licensed FR229934, an investigational compound being studied for the treatment of erectile dysfunction (ED) from Fujisawa Pharmaceutical Co., Ltd. Under the license agreement, TAP has exclusive rights to develop this compound and market it on a worldwide basis, except for Japan, South Korea, China and the Republic of China (Taiwan). More... |
Ars Medica Home | Ex Libris | Vidyya |
Subscription Information | About Vidyya | Vidyya Archives |
Editor: Susan K. Boyer, RN
© RAmEx Ars Medica, Inc. All rights reserved.